• Home
  • Market
  • US Market Open: Pfizer, Amgen, Johnson & Johnson Shares Plunge Amid Trump’s Pharma Tariff Concerns
US Market Open: Pfizer, Amgen, Johnson & Johnson Shares Plunge Amid Trump’s Pharma Tariff Concerns

US Market Open: Pfizer, Amgen, Johnson & Johnson Shares Plunge Amid Trump’s Pharma Tariff Concerns

Pharmaceutical stocks took a hit as Wall Street opened on Wednesday, April 9, amid rising concerns over new tariffs on drug imports. The trade tensions between the United States and various global economies have left investors jittery, causing major pharmaceutical companies like Pfizer, Amgen, Johnson & Johnson, and Eli Lilly to see declines in their stock prices.

Market Overview

As the trading day began, Pfizer Inc. experienced a notable drop, with its shares down 2.56% at $21.31 by 10:11 a.m. EDT, following an opening price of $21.11. Similarly, Johnson & Johnson’s stock decreased by 2.37%, trading at $146.45, down from $150 at the previous close.

  • Eli Lilly & Co.: Down over 3% at $701.25, compared to $726.24 previously.
  • Amgen: Shares fell 2.48% to $273.23, down from $280.26.
  • Merck & Co.: Also saw a decline of over 3%, trading at $76.61.

Wall Street Indices at a Glance

The overall market sentiment reflected in the major indices was mixed:

  • Dow Jones Industrial Average (DJIA): Opened 0.68% lower at 37,387.91 points, slightly recovering to 37,708 during early trading.
  • S&P 500: Dropped 0.35% to 4,965.28 points, although it later traded 0.52% higher.
  • Nasdaq Composite: Gained 0.18%, reaching 15,295.441 points, showing a 1.5% increase earlier in the session.

Impact of Proposed Tariffs

President Donald Trump announced on April 8 that a significant tariff on pharmaceutical imports would soon be enforced, shaking investor confidence further. During his address, he stated, "We’re going to tariff our pharmaceuticals… a major tariff on pharmaceuticals will be announced shortly."

This development marks a shift from the previous exemption that the pharmaceutical sector enjoyed under last week’s tariff announcements. With many pharmaceutical companies relying on foreign sources for raw materials, the potential duty on imports raises concerns about the supply chain and pricing strategies.

See also  Asia-Pacific Markets Surge as Trump Halts Tariffs on Consumer Electronics

Investor Sentiment and Future Outlook

The apprehension surrounding U.S. tariffs is palpable, making investors wary of pharmaceutical stocks. As global pharmaceutical companies navigate these uncertain waters, the market will likely continue to react to news regarding trade policies and tariff implementations.

For more insights into market trends and updates on U.S. stocks, stay informed about the latest developments.

Related Post

Top 3 Stocks Under ₹100 to Buy Now: Mehul Kothari of Anand Rathi's Expert Picks
Top 3 Stocks Under ₹100 to Buy Now: Mehul Kothari of Anand Rathi’s Expert Picks
ByAbhinandanApr 19, 2025

The Indian stock market has seen significant gains, marking its fourth consecutive day of increases.…

Stock Market Weekly Highlights: Top Gainers Soar, Losers Plummet – Discover the Biggest Movers!
Stock Market Weekly Highlights: Top Gainers Soar, Losers Plummet – Discover the Biggest Movers!
ByAbhinandanApr 19, 2025

The Indian financial sector is experiencing significant activity, highlighted by the Reserve Bank of India’s…

Sensex Soars 4,700 Points and Nifty 50 Surpasses 23,800: Uncovering the Reasons Behind Four Days of Indian Stock Market Gains!
Sensex Soars 4,700 Points and Nifty 50 Surpasses 23,800: Uncovering the Reasons Behind Four Days of Indian Stock Market Gains!
ByAbhinandanApr 19, 2025

The Indian stock market has surged significantly in the past four days, recovering from earlier…

Oil Posts Seventh Weekly Loss on Easing War Risk, Tariff Chaos
Positive FPI Inflows Surge to ₹8500 Crore this Week Amid Shortened Trading Days: Insights from NSDL Data
ByAbhinandanApr 19, 2025

Foreign investors returned to the Indian stock market, injecting approximately ₹8,500 crore during a short…

Leave a Reply

Your email address will not be published. Required fields are marked *

JOIN US

Get Newsletter

Subscribe our newsletter to get the best stories into your inbox!